Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.52
-C$0.05(-9.62%)
At close: 4:00 PM EDT
C$0.52
-C$0.05(-9.62%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.99
Previous CloseN/A
Volume8.89K
Average Volume (3M)77.99K
Market Cap
C$26.51M
Enterprise ValueC$37.05M
Total Cash (Recent Filing)C$436.82K
Total Debt (Recent Filing)C$5.70M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding58,909,430
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused IOL Development & IPOcumetics' explicit focus on a single intraocular lens program, combined with disclosed intellectual property and regulatory/commercialization planning, creates a durable product development roadmap. That focused R&D and IP activity supports a clear path to commercialization and defensibility versus unfocused peers, improving long-term strategic clarity and potential to capture ophthalmic IOL market opportunities once approvals and manufacturing scale are achieved.
Cash Loss Reflects Cash RealityFree cash flow closely tracking net losses indicates losses are primarily cash-based rather than driven by large non-cash accounting items. That alignment improves transparency of true funding needs, making multi-month cash runway and financing plans easier to model and reducing uncertainty around the scale of future capital required to advance clinical and commercialization milestones.
Lean Operating FootprintA very small employee base suggests a lean cost structure appropriate for a pre-revenue medical device developer. Maintaining low fixed overhead can extend runway per financing round, enabling the company to allocate scarce capital to critical development, regulatory and IP activities over the coming months while minimizing structural burn before commercialization scale-up.
Bears Say
No Revenue To DateThe absence of any recorded revenue indicates the company remains pre-commercial. Without product sales, the business is fully dependent on external capital to fund continued R&D, trials, regulatory work and eventual launch. This elevates execution and financing risk over the next 2–6 months and prolongs uncertainty about market acceptance and sustainable cash generation.
Escalating Net LossesRapidly widening net losses demonstrate accelerating cash consumption as development and operating activities scale. Increasing annual losses raise near-term financing needs, make dilutive capital raises more likely, and increase execution pressure to achieve regulatory milestones or partnerships that can materially alter the firm's funding trajectory within months.
Deteriorated Balance Sheet & Rising DebtSharply higher debt and deeply negative equity limit financial flexibility and increase solvency risk. A small asset base alongside rising leverage constrains the company's ability to secure favorable financing, may force diluted equity issuance or expensive debt, and reduces cushion for unexpected delays in approvals or commercialization efforts over the medium term.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$26.51M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 27 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 58,909,430 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―